436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment - Ciardiello, F.; Yoshino, T.; Modest, D.P.; Martin Fernandez, L.; Roby, L.; Fougeray, R.; Lockhart, B.P.; Tabernero, J. (Annals of Oncology, 2022)